clinical trial · NCT03381274
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Carcinoma, Non-Small-Cell LungOleclumabOsimertinibAZD4635
brief summary
The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.
started
May 8, 2018
primary completion
May 24, 2021
completion
Apr 16, 2026
last updated
Mar 11, 2026
official title
A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol